Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer

Krill, Lauren; Tewari, Krishnansu S.

doi:10.1517/14656566.2015.1010511

Cited by 12 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incremental survival benefit in patients with stage IVB with the addition of IMT after applying propensity score analysis extends to prior retrospective studies [ 5 , 10 , 16 , 20 , 21 , 23 ] and is consistent with results from phase II and phase III clinical trials [ 23 , 24 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 44 , 45 ]. Outside of clinical trials, Perkins et al [ 25 ] reported a 24-month improvement in overall survival following CT + EBRT (whole pelvic radiation) vs. CT in a small multi-site retrospective cohort study with a median follow-up of 9 months.…”

Section: Discussionsupporting

confidence: 80%

“…In 2014, Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), was FDA-approved for use for metastatic and recurrent cervical cancer following the completion of the randomized phase III trial, GOG-240 [ 23 ]. The addition of Bevacizumab to CT for the treatment of advanced-stage cervical cancer further increased the median survival to 17.0 months [ 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States

Sitler,

Tian,

Hamilton

et al. 2024

Cancers

View full text Add to dashboard Cite

Purpose: To investigate IMT use and survival in real-world stage IVB cervical cancer patients outside randomized clinical trials. Methods: Patients diagnosed with stage IVB cervical cancer during 2013–2019 in the National Cancer Database and treated with chemotherapy (CT) ± external beam radiation (EBRT) ± intracavitary brachytherapy (ICBT) ± IMT were studied. The adjusted hazard ratio (AHR) and 95% confidence interval (CI) for risk of death were estimated in patients treated with vs. without IMT after applying propensity score analysis to balance the clinical covariates. Results: There were 3164 evaluable patients, including 969 (31%) who were treated with IMT. The use of IMT increased from 11% in 2013 to 46% in 2019. Age, insurance, facility type, sites of distant metastasis, and type of first-line treatment were independently associated with using IMT. In propensity-score-balanced patients, the median survival was 18.6 vs. 13.1 months for with vs. without IMT (p < 0.001). The AHR was 0.72 (95% CI = 0.64–0.80) for adding IMT overall, 0.72 for IMT + CT, 0.66 for IMT + CT + EBRT, and 0.69 for IMT + CT + EBRT + ICBT. IMT-associated survival improvements were suggested in all subgroups by age, race/ethnicity, comorbidity score, facility type, tumor grade, tumor size, and site of metastasis. Conclusions: IMT was associated with a consistent survival benefit in real-world patients with stage IVB cervical cancer.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States

Sitler,

Tian,

Hamilton

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…In 2014, bevacizumab was approved for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, based on the results of AURELIA clinical trials comparing bevacizumab plus chemotherapy with chemotherapy alone ( 20 , 21 ). Also in 2014, bevacizumab was approved in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent or metastatic cervical cancer ( 22 , 23 ).…”

Section: Treatment Strategiesmentioning

confidence: 99%

Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)

Maj

Papiernik

Wietrzyk

2016

International Journal of Oncology

120

View full text Add to dashboard Cite

The discovery of tumor angiogenesis opened a new path in fighting cancer. The approval of different antiangiogenic agents, most targeting vascular endothelial growth factor (VEGF) signaling, has either increased the effectiveness of standard chemotherapy or even replaced it by offering better patient outcomes. However, an increasing number of preclinical and clinical observations have shown that the process of angiogenesis is far from clearly understood. Apart from targeting the VEGF pathway, novel strategies aim to influence other molecular factors that are involved in tumor angiogenesis. In addition, naturally occurring compounds seem to offer additional agents for influencing angiogenesis. The first concept of antiangiogenic therapy aimed to destroy tumor vessels, while it turned out that, paradoxically, antiangiogenic drugs normalized vasculature and as a result offered an improvement in chemotherapeutic delivery. In order to design an effective treatment schedule, methods for detecting the time window of normalization and biomarkers predicting patient response are needed. The initial idea that antiangiogenic therapy would be resistance-free failed to materialize and currently we still face the obstacle of resistance to antiangiogenic therapy.

show abstract

“…Treatment options consist of radical hysterectomy with lymphadenectomy and radiotherapy in earlier stages and cisplatin-containing chemoradiotherapy in stages II and above [76]. Recently, the anti-VEGF antibody bevacizumab has also been approved for treatment of advanced stages [78].…”

Section: Cervical Cancermentioning

confidence: 99%

Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters

et al. 2015

View full text Add to dashboard Cite

Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer

Cited by 12 publications

References 28 publications

Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States

Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States

Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)

Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters

Contact Info

Product

Resources

About